|
|
Title:
Hydroxyapatite grafted fumarate based macromers for biodegradable
composites
United States Patent: 7,642,300
Issued: January 5, 2010
Inventors:
Yaszemski; Michael J. (Rochester,
MN), Currier; Bradford L. (Rochester, MN), Jabbari; Esmaiel (Columbia,
SC), Lu; Lichun (Rochester, MN)
Appl. No.: 10/562,591
Filed: June 29, 2004
PCT Filed: June 29, 2004
PCT No.: PCT/US2004/020842
371(c)(1),(2),(4) Date: June
13, 2006
PCT Pub. No.: WO2005/019313
PCT Pub. Date: March 03,
2005
|
|
|
Patheon
|
Abstract
A composition is disclosed which
comprises (i) a macromer prepared by reacting an unsaturated diacid having
a carbon-carbon double bond and a saturated diacid, and (ii) a bioactive
ceramic grafted to the macromer. In one embodiment, the unsaturated diacid
having a carbon-carbon double bond is fumaric acid, the saturated diacid
is compatible with fumaric acid and poly(propylene fumarate) such as
succinic acid, glutaric acid, adipic acid, pimelic acid, suberic acid,
azelaic acid, sebacic acid and mixtures thereof, and the bioactive ceramic
is hydroxyapatite. In another embodiment, hydroxyapatite is grafted with a
biodegradable and crosslinkable macromer comprising silane units
alternating with furnarate and adipate units.
Description of the
Invention
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to ceramic grafted macromers that are useful as a
filler in biodegradable composites, and more particularly to the synthesis
of hydroxyapatite grafted with fumarate based degradable and crosslinkable
macromers for use as a filler in biodegradable composites.
2. Description of the Related Art
Bioactive ceramics such as hydroxyapatite have been used for a variety of
applications including bone fixation devices and implant coating.
Synthetic hydroxyapatite is especially attractive to serve as a filler
material for biodegradable polymer-ceramic composites (see, for example,
Lu et al., Synthetic bone substitutes, Curr. Opin., Orthop., 11 (2000)
383-390). Advantages include similarity in composition to bone mineral,
bioactivity and promotion of cellular function, and osteoconductivity.
Previous studies indicate that interfacial bonding between the
hydroxyapatite surface and the matrix can significantly improve mechanical
properties of polymer-ceramic composites (see, for example, Porter et al.,
Mechanical properties of a biodegradable bone regeneration scaffold, J.
Biomech. Eng. 122 (2000) 286-288; Zhu et al., Mechanical properties of
biodegradable poly(propylene fumarate)/bone fiber composites, Trans. Soc.
Biomater., 25 (2002)260; and Deb et al., Hydroxyapatite-polyethylene
composites; effect of grafting and surface treatment of hydroxyapatite, J.
Mater, Sci.: Mater. Med., 7 (1996) 191-193).
Thus, there is a continuing need for improved methods for incorporating
hydroxyapatite into biodegradable polymer-ceramic composites. In
particular, there is a need for methods for achieving improved interfacial
bonding between hydroxyapatite and the matrix of biodegradable polymer-hydroxyapatite
composites.
SUMMARY OF THE INVENTION
The present invention provides for the synthesis of ceramic grafted
degradable and crosslinkable macromers which can chemically bond to a
biodegradable matrix. For instance, hydroxyapatite grafted with fumarate
based degradable and crosslinkable macromers can be used as a filler in
biodegradable composites. As a result, biodegradable and bioactive
composites with improved mechanical properties can be developed for
orthopedic applications.
In one aspect, the invention provides for the synthesis of a composition
wherein a bioactive ceramic, hydroxyapatite, is grafted to a biodegradable
and crosslinkable macromer comprising substituted or unsubstituted silane
units alternating with fumarate and saturated diacid (e.g., adipate)
units. The saturated diacid units serve as a flexible spacer between the
rigid fumarate units.
In another aspect, the invention provides for a biodegradable composite
including a polymeric matrix and the hydroxyapatite grafted macromer
crosslinked to the matrix. The matrix has a carbon-carbon double bond, and
in one embodiment is poly(propylene fumarate). The composite is suitable
as a scaffold for tissue regeneration such as bone regeneration.
In yet another aspect, the invention provides a crosslinkable,
biodegradable material including a polymer having a carbon-carbon double
bond, the hydroxyapatite grafted macromer, and a crosslinking agent for
crosslinking the polymer and the hydroxyapatite grafted macromer. The
crosslinkable, biodegradable material may be used as a bone substitute or
a bone cement. Preferably, the polymer is poly(propylene fumarate), and
the crosslinking agent is a free radical initiator such as benzoyl
peroxide.
DETAILED DESCRIPTION OF THE INVENTION
In this invention, a bioactive ceramic, such as hydroxyapatite
(Ca.sub.10(PO.sub.4).sub.6(OH).sub.2) powder, is grafted with macromers
that contain units derived from an unsaturated diacid having a
carbon-carbon double bond (e.g., fumarate units). When used as a filler,
the grafted macromer can be covalently crosslinked to a matrix containing
unsaturated double bonds through the unsaturated double bonds found in the
units derived from the unsaturated diacid (e.g., fumarate groups). In
addition, the ester bonds in the unsaturated diacid (e.g., fumarate
groups) are susceptible to hydrolytic cleavage, which promote the
degradation of the macromer.
The macromer is prepared by reacting various components. The main
component in the reaction mixture used to synthesize the macromer is the
unsaturated diacid (e.g., fumaric acid) that contains an unsaturated
double bond and two hydrolyzable ester groups. After the bioactive ceramic
(e.g., hydroxyapatite) is grafted to the macromer and the grafted macromer
is mixed with a biodegradable polymeric matrix having a carbon-carbon
double bond, such as poly(propylene fumarate), the unsaturated
carbon-carbon double bonds of the fumarate groups of the poly(propylene
fumarate) in the matrix phase can inter-crosslink with the unsaturated
carbon-carbon double bonds of the macromer in the grafted hydroxyapatite.
This inter-crosslinking between the bioactive ceramic (e.g. hydroxyapatite)
grafted macromer and the matrix phase significantly improves the
mechanical strength of this biodegradable and bioactive composite
especially in the torsional mode and in the bending mode.
The second component of the macromer is a spacer which imparts flexibility
to the macromer therefore increasing the reactivity of the unsaturated
diacid (e.g., fumarate groups) of the macromer with the fumarate groups of
the matrix. The number of fumarate groups per macromer or the density of
the fumarate groups on the graft can be controlled by varying the ratio of
the spacer group to the fumarate group. The spacer is preferably a
saturated diacid monomer compatible with fumaric acid and poly(propylene
fumarate) selected from saturated diacid organic compounds including,
without limitation, succinic acid, glutaric acid, adipic acid, pimelic
acid, suberic acid, azelaic acid, sebacic acid, and the like. By
`compatible`, we mean the saturated diacid does not interfere with the
reaction between fumaric acid and poly(propylene fumarate) and the
saturated diacid does not degrade fumaric acid or poly(propylene fumarate).
The third component of the macromer is a silane coupling agent that links
the main component to the spacer to form a macromer. Example silane
coupling agents include substituted or unsubstituted silanes such as
dichlorodimethylsilane that form substituted or unsubstituted silane links
between the fumarate and spacer monomers to form a macromer.
The fourth component of the macromer is a capping agent that restricts the
grafting to one end of the macromer chain. In one embodiment, the fourth
component is selected from alkyl esters (e.g., monomethyl ester) of the
spacer monomer.
The bioactive ceramic may be bioactive ceramic powders with particle sizes
ranging from nanometers to micrometers. These sizes are suitable for
grafting in this invention. By bioactive, we mean a substance which
affects the structure or function of the body or which becomes
biologically active or more active after it has been placed in a
predetermined physiological environment. Hydroxyapatite
(Ca.sub.10(PO.sub.4).sub.6(OH).sub.2) powder is the preferred bioactive
ceramic, and preferably has a particle size of less than 10,000
nanometers. The bioactive ceramic may be treated to facilitate grafting to
the macromer. In one embodiment, hydroxyapatite is silicated to facilitate
grafting to the macromer.
An exemplary procedure for preparation of the macromer and grafting with
fumaric acid as the main component, adipic acid as the spacer and adipic
acid monomethyl ester as the capping agent is as follows. First,
hydroxyapatite whiskers are silicated with sodium metasilicate.
Second, the end-capped macromer is synthesized. To prepare the macromer,
fumaric acid, adipic acid, and adipic acid monomethyl ester are added to
dimethylchlorosilane. Next, polycondensation of
bis(dimethylchlorosilyl)-fumarate, bis(dimethylchlorosilyl)-adipate, and
dimethylchlorosilyladipate monomethyl ester is carried out to obtain the
fumarate-adipate macromer capped with adipic acid monomethyl ester at one
end and with reactive chlorosilane at the other end. After completion of
the polycondensation reaction, the reactive chlorosilane end of the
macromer chains is quenched with excess methanol to obtain a macromer
capped with adipic acid monomethyl ester and methoxysilane.
Third, the macromer is grafted to the surface of the hydroxyapatite
nanoparticles. The macromer is dissolved in an acetone-water mixture and
the silicated hydroxyapatite is added to the mixture. After, removal of
acetone and water, the macromer and silicated hydroxyapatite are condensed
to produce the macromer with grafted hydroxyapatite.
EXAMPLES
The following Examples have been presented in order to further illustrate
the invention and are not intended to limit the invention in any way.
A. Experimental
For maximum interfacial interaction and extent of grafting, hydroxyapatite
nanoparticles with average size of 50 nm. were used in this study.
Hydroxyapatite (HA) whiskers (Berkely Advanced Biomaterials, San Leandro,
Calif.) with long and short axis of 100 and 20 nm, respectively, were used
for grafting (See FIG. 1a (see Original Patent)). The HA was silicated
according to the method described in Krorasani et al., Modified
hydroxyapatite reinforced PEMA bone cement, in Bone Ceramics, Yamamura,
Kokubo and Nakamura, Eds., Kobunshi Kankokai, Kyoto, Japan, 1992, pp.
225-232. Briefly, 1 gram of sodium metasilicate (SMS) (Aldrich, Milwaukee,
Wis.) was dissolved in 50 ml. of distilled deionized water (DDW), 1 gram
of HA was added, and the mixture was stirred for 3 hours. The pH was
adjusted to 6.8 with hydrochloric acid and the mixture was allowed to stir
overnight. The mixture was centrifuged and the solid silicated HA (SiHA)
product was dried in vacuum at 150.degree. for 2 hours.
To prepare end-capped dimethyldichlorosilane alternating fumaric acid/adipic
acid (SFA) macromer, the procedure in Najafi et al., Preparation of
biodegradable poly[(dimethyldichlorosilane)-alt-(fumaric acid/sebasic
acid)]-co-PEG block copolymer, Polymer, 43 (2002) 6363-6368, was modified
to cap the chain ends of the macromer with methoxysilane and adipic acid
monomethyl ester (mAA), respectively. All reactants were obtained from
Aldrich and they were used as received. In a typical procedure, 0.2 mol
fumaric acid (FA), 0.2 mol adipic acid (AA), and 0.045 mol of mAA were
added to a three-neck reaction flask containing 1.335 mol of
dimethylchlorosilane (DMCS) in dry nitrogen atmosphere and under stirring.
The silation reaction was carried out under reflux for 12 hours and the
evolved HCl was captured in aqueous NaOH. Next, polycondensation of
bis(dimethylchlorosilyl) fumarate, bis(dimethylchlorosilyl)adipate, and
dimethylchlorosilyladipate monomethyl ester was carried out under vacuum
of 10 mmHg at 120.degree. C. for 4 hours to obtain the SFA macromer capped
with mAA at one end and with reactive chlorosilane at the other end. The
DMCS by-product produced during the polycondensation reaction was
continuously removed under vacuum. After completion of polycondensation
reaction, the reactive chlorosilane end of the SFA chains was quenched
with excess methanol to obtain SFA macromer capped with mAA and
methoxysilane (mSi). Excess methanol was removed by rotovaporation; the
macromer was redissolved in methylene chloride and precipitated twice in
cold ether. The macromer was dried under vacuum for at least 12 hours and
stored at -20.degree. C. before grafting. For comparison, 3-acryloylpropyl
trimethoxysilane (AcHA) was also grafted to SiHA using the same procedure.
The following procedure was used to graft the macromer to the surface of
SiHA. The SFA macromer was dissolved in 50 ml. of 70/30 acetone-water
mixture in a reaction flask and the SiHA was added to the solution in
nitrogen atmosphere and under vigorous mixing. After, removal of acetone
and water at 100.degree. C., the macromer and SiHA were condensed at
120.degree. for 2 hours. The reaction by-product, methanol, was
continuously removed during the reaction. The grafted HA was washed at
least 3 times with THF, centrifuged, and dried under vacuum. The product
was stored at -20.degree. C. until use.
.sup.1H-NMR was used to confirm the presence of the fumarate and adipate
groups in the macromer. .sup.1H-NMR spectrum was recorded with a Bruker
Avance 500 MHz system (Bruker Analytik GmbH, Rheinstetten, Germany) at
ambient temperature. Pulse angle, pulse duration, delay time, acquisition
time, resolution, and number of scans was 90.degree., 6 .mu.sec, 7 s. 3 s.
0.17 Hz, and 32, respectively. Macromer solution was prepared with
deuterated chloroform (99.8 atom % Deutertaed, Aldrich) at a concentration
of 50 mg/ml containing 1% v/v trimethylsilane (TMS) as the internal
standard.
FTIR, thermogravimetric analyzer (TGA), and energy-dispersive x-ray
spectroscopy (EDS) were used to characterize the grafted hydroxyapatite.
An FTS-40 FTIR (Bio-Rad, Hercules, Calif.) was used to collect the
spectrum in a dry nitrogen atmosphere with 200 averaged scans and
resolution of 2 cm.sup.-1. The grafted HA was suspended by sonication in
perfluorodecalin (Aldrich) and injected in a 10 .mu.m.times.3 mm cavity
between two CaF.sub.2 disks (Wilmad Glass, Buena, N.J.). Perfluorodecalin
between two CaF.sub.2 disks was used as the reference cell.
A TGA 2050 thermogravimetric analyzer (TA Instruments, New Castle, Del.)
was used to measure the extent of grafting. Approximately 5 mg. of the
grafted hydroxyapatite was heated at a rate of 20.degree. C./min in an air
atmosphere and the weight loss was recorded as a function of time. The TGA
was calibrated for weight and temperature using 100 mg class M standard
and the curie temperature of nickel, respectively.
For energy-dispersive x-ray spectroscopy, the grafted hydroxyapatite
powder was embedded in a Spurr resin inside a plastic BEEM capsule
(Electron Microscopy Sciences, Fort Washington, Pa.) and it was allowed to
polymerize overnight in a convection oven. The blocks were sectioned with
an Ultra S cryoultramicrotome (Leica, Deerfield, Ill.) to a thickness of
80 nm. The unstained sections were mounted on copper grids and the emitted
x-ray energy of the elements were collected using a Noran Vantage X-ray
Microanalysis System (Noran Instruments, Middleton, Wis.) with a Philips
CM12 STEM PW6030 transmission electron microscope (Philips, Eindhoven,
Netherlands).
B. Results and Discussion
The .sup.1H-NMR spectrum of SFA macromer is shown in FIG. 1b (see Original Patent).
The shift with peak position at 6.9 ppm is due to hydrogens of fumarate
groups of FA. The shifts with peaks centered at 3.7 and 3.8 ppm are due to
methylene hydrogens of AA and mAA attached to two methylene groups. The
shifts with peaks centered at 2.4 and 1.7 ppm are due to methylene groups
hydrogens of AA and mAA attached to a methylene group and a carboxyl
group. The shift with peak position at 0.1 ppm is due to methyl hydrogens
of the methoxy group of mAA. According to the NMR spectrum, the ratio of
FA:AA:mAA in the macromer is 1:2:1, which is different from the feed
ration of 2:2:0.45. This indicates that AA and mAA are preferentially
incorporated into the macromer compared to FA.
FIG. 2 (see Original Patent) shows the FTIR of the HA versus AcHA and SFA
grafted HA. The absorption bands with peak positions centered at 2900 and
2950 cm.sup.-1 in the spectrum of AcHA are due to CH stretching vibrations
of CH and CH.sub.2 groups of 3-acryloxypropyl which is absent in the
spectrum of HA. Likewise, the bands with peaks centered at 2885 and 2985
cm.sup.-1 in the spectrum of SFA-HA are due to CH stretching vibrations of
CH.sub.2 groups of adipate which is absent in the HA spectrum. In the
spectra of AcHA and SFA-HA, the band with peak centered at 1720 cm.sup.-1
is due to C.dbd.O stretching vibration carboxyl groups which is absent in
the HA spectrum. In the AcHA spectrum, the weak absorption band with peak
centered at 1635 cm.sup.-1 is due to C.dbd.C stretching vibration of
CH.sub.2.dbd.CHCOO-vinyl group of Ac which is absent in the spectra of HA
and SFA-HA. In the SFA-HA spectrum, the weak absorption band with peak
centered at 1660 cm.sup.-1 is due to C.dbd.C stretching vibration of
fumarate groups of SFA which is absent in the spectra of HA and AcHA.
In FIG. 3 (see Original Patent), the energy-dispersive x-ray spectroscopy
spectrum of HA is compared with SFA-HA. Both spectra show emission bands
at 2.0 KeV due to phosphorous in HA, at 3.7 and 4.0 KeV due to calcium in
HA, and at 2.6 KeV due to chlorine in the embedding resin. In addition,
there is a peak centered at 1.7 KeV due to Silicon in the SFA-HA spectrum
due to silicate and dimethylsilane groups of the graft which is absent in
the HA spectrum. The EDS and FTIR spectra indicate that the SFA macromer
was successfully grafted to the HA surface. The presence of C.dbd.C
absorption band in the FTIR spectrum of SFA-HA indicate that the grafted
HA can participate in intra- and inter-molecular crosslinking.
The weight loss versus temperature for HA, AcHA, and SFA-HA is shown in
FIG. 4 (see Original Patent). As the temperature was increased, the
degradation of the graft in air for AcHA and SFA-HA commenced at
350.degree. C. but it ended at 600.degree. C. and 700.degree. C.,
respectively. For AcHA graft, there was a continuous weight loss of the
graft between temperatures of 350.degree. and 600.degree. C. However, for
SFA-HA, the weight loss occurred step-wise in three steps centered at
350.degree., 500.degree., and 700.degree. C., respectively. The step-wise
degradation of SFA-HA graft was due to different degradation temperature
of the constituents of the graft, which included fumarate, adipate, and
dimethylsilane groups. According to thermogravimetric analyzer data in
FIG. 4, the extent of grafting for AcA and SFA-HA were 12% and 15% by
weight, respectively.
Thus, an example macromer including dimethylsilane units alternating with
fumarate and adipate units was synthesized. The adipate and fumarate units
of the macromer are degradable and the fumarate groups can be crosslinked.
The macromer was capped at one end with methoxysilane group for grafting
to silicated hydroxyapatite. The macromer was grafted to silicated
hydroxyapatite and characterized by FTIR, energy-dispersive x-ray
spectroscopy, and thermogravimetric analyzer. FTIR confirmed the presence
of fumarate and adipate groups on the hydroxyapatite surface. Energy-dispersive
x-ray spectroscopy confirmed the presence of silicon on the hydroxyapatite
surface. According to thermogravimetric analyzer results, the extent of
grafting was 15% by weight. These biodegradable and crosslinkable
macromers grafted to hydroxyapatite can be useful for development of
composite biomaterials in orthopedic tissue engineering applications.
INDUSTRIAL APPLICABILITY
The present invention relates to the synthesis of hydroxyapatite powder
grafted with fumarate based degradable and crosslinkable macromers for use
as a filler in biodegradable composites
Claim 1 of 22 Claims
1. A composition comprising: a macromer
prepared by reacting an unsaturated diacid having a carbon-carbon double
bond and a saturated diacid, wherein the unsaturated diacid having a
carbon-carbon double bond is fumaric acid; and a bioactive ceramic grafted
to the macromer, wherein the bioactive ceramic is hydroxyapatite grafted
to the macromer by way of silicate groups. ____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|